| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
We proposed possibility that LCH has both neoplastic character and reactive character. As a trigger of the reactive origin we proposed the dermotropic Merkel cell polyomavirus (MCPyV) as a pathogenic agent. The lesional hyperreactivity may define the clinical courses of LCH. Though primary infection with MCPyV may play a significant pathogenic role in LCH, other mechanisms might also play important roles in LCH.
As clues to understand these mechanisms, we think serum biomarkers are important. LCH consists of two subtypes: single-system LCH (SS-LCH) with favorable prognosis and multisystem LCH (MS-LCH) with poor prognosis. LCH is also classified as either LCH developed in at least one high-risk organ (RO (+)) or LCH developed in organ without high-risk organ (LCH-RO (-)). As a preliminary analysis we already delineated 2 candidate biomarkers in sera which differentiate the LCH from controls, MS-LCH from SS-LCH, or LCH-RO (+) from LCH-RO (-), respectively.
|
